| Literature DB >> 20211437 |
Yoram Etzion1, Anthony J Muslin.
Abstract
In traditional pure protein high-throughput drug screens, also called in vitro screens, individual compounds from a small molecule collection are tested to determine whether they inhibit the enzymatic activity or binding properties of a purified target protein. In contrast, phenotypic high-throughput drug screens, also called chemical genetic or in vivo screens, investigate the ability of individual compounds from a collection to inhibit a biological process or disease model in live cells or intact organisms. In this review, the role of phenotypic screening techniques to identify novel therapeutic agents for the treatment of cardiovascular disease will be discussed. (c) 2009 Elsevier Inc. All rights reserved.Entities:
Mesh:
Substances:
Year: 2009 PMID: 20211437 PMCID: PMC2836266 DOI: 10.1016/j.tcm.2009.12.006
Source DB: PubMed Journal: Trends Cardiovasc Med ISSN: 1050-1738 Impact factor: 6.677